Evidence map›Paper›PMID 34068924›Full record

ArticleAntioxidants (Basel, Switzerland)2021

Hidrox

Roberta Fusco, Angela Trovato Salinaro, Rosalba Siracusa, Ramona D'Amico, Daniela Impellizzeri, Maria Scuto, Maria Laura Ontario, Roberto Crea, Marika Cordaro, Salvatore Cuzzocrea and 2 more

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Modulation of TLR4/NFκB Pathways in Autoimmune Myocarditis.Antioxidants (Basel, Switzerland) · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Roberta FuscoDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.ORCID 0000-0003-0223-1403
Angela Trovato SalinaroDepartment of Biomedical and Biotechnological Sciences, University of Catania, 95131 Catania, Italy.ORCID 0000-0003-2377-858X
Rosalba SiracusaDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.ORCID 0000-0001-7868-2505
Ramona D'AmicoDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.ORCID 0000-0003-0389-3871
Daniela ImpellizzeriDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.ORCID 0000-0001-9492-3161
Maria ScutoDepartment of Biomedical and Biotechnological Sciences, University of Catania, 95131 Catania, Italy.ORCID 0000-0003-1019-5158
Maria Laura OntarioDepartment of Biomedical and Biotechnological Sciences, University of Catania, 95131 Catania, Italy.
Roberto CreaOliphenol LLC, 26225 Eden Landing Road, Unit C, Hayward, CA 94545, USA.
Marika CordaroDepartment of Biomedical, Dental and Morphological and Functional Imaging, University of Messina, Via Consolare Valeria, 98125 Messina, Italy.
Salvatore CuzzocreaDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.ORCID 0000-0001-6131-3690
Rosanna Di PaolaDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.ORCID 0000-0001-6725-8581
Vittorio CalabreseDepartment of Biomedical and Biotechnological Sciences, University of Catania, 95131 Catania, Italy.ORCID 0000-0002-0478-985X
University of Messina · ITUniversity of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvery year, men use cyclophosphamide to treat various cancers and autoimmune diseases. On the one hand, this chemotherapy often has the beneficial effect of regressing the tumor, but on the other hand, it leads to infertility due to excessive oxidative stress and apoptosis in the testes caused by its metabolite, acrolein.

methodsThe objective of this study was to evaluate the beneficial power of a new compound called Hidrox

resultsOur study confirms that the use of cyclophosphamide causes a series of sperm and histological alterations strongly connected with oxidative stress, lipid peroxidation, and apoptosis.

conclusionOur results demonstrate for the first time that Hidrox

Indexed as

cyclophosphamideinflammationNrf2oxidative stress

Identifiers

PMID34068924
PMCPMC8156985
OpenAlexW3160377061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.